The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low
- PMID: 15755209
- DOI: 10.1489/1544-581X(2004)72<493:TRRIML>2.0.CO;2
The relapse rate in MB leprosy patients treated with 2-years of WHO-MDT is not low
Abstract
A group of multibacillary patients is clearly at high risk for relapse following 2-yr WHO-MDT. Relapse is largely confined to BL or LL patients with a high BI initially, and occurs long after the discontinuation of therapy. This important group of patients at risk for treatment failure presents several important issues: the need to identify those at risk and the operational requirements needed for their long term follow-up. Also, this group of patients might well benefit from an alternative antimicrobial regimen from the outset, as well as upon relapse.
Comment in
-
A need for clarification of the classification criteria for leprosy patients.Int J Lepr Other Mycobact Dis. 2005 Dec;73(4):280-1; author reply 281-2. Int J Lepr Other Mycobact Dis. 2005. PMID: 16830638 No abstract available.
Similar articles
-
Incidence of late lepra reaction among multibacillary leprosy patients after MDT.Int J Lepr Other Mycobact Dis. 1995 Mar;63(1):18-22. Int J Lepr Other Mycobact Dis. 1995. PMID: 7730714
-
Two microbiological relapses in a patient with lepromatous leprosy.Lepr Rev. 2008 Sep;79(3):331-4. Lepr Rev. 2008. PMID: 19009984
-
Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.Int J Lepr Other Mycobact Dis. 2003 Dec;71(4):308-19. doi: 10.1489/1544-581X(2003)071<0308:LEOYWM>2.0.CO;2. Int J Lepr Other Mycobact Dis. 2003. PMID: 14763888 Clinical Trial.
-
Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.Int J Lepr Other Mycobact Dis. 1992 Sep;60(3):421-35. Int J Lepr Other Mycobact Dis. 1992. PMID: 1474281 Review.
-
Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia.Int J Lepr Other Mycobact Dis. 1992 Sep;60(3):436-44. Int J Lepr Other Mycobact Dis. 1992. PMID: 1474282 Review.
Cited by
-
Vaccination with the ML0276 antigen reduces local inflammation but not bacterial burden during experimental Mycobacterium leprae infection.Infect Immun. 2009 Dec;77(12):5623-30. doi: 10.1128/IAI.00508-09. Epub 2009 Sep 28. Infect Immun. 2009. PMID: 19786561 Free PMC article.
-
Primary multidrug-resistant leprosy, United States.Emerg Infect Dis. 2013 Jan;19(1):179-81. doi: 10.3201/eid1901.120864. Emerg Infect Dis. 2013. PMID: 23260417 Free PMC article. No abstract available.
-
Reactions following completion of 1 and 2 year multidrug therapy (MDT).Am J Trop Med Hyg. 2010 Sep;83(3):637-44. doi: 10.4269/ajtmh.2010.09-0586. Am J Trop Med Hyg. 2010. PMID: 20810832 Free PMC article.
-
Report on an unusual case of leprosy from Germany: just an exception of the rule?Infection. 2019 Dec;47(6):1065-1069. doi: 10.1007/s15010-019-01349-8. Epub 2019 Aug 27. Infection. 2019. PMID: 31456174
-
Role of histopathological, serological and molecular findings for the early diagnosis of treatment failure in leprosy.BMC Infect Dis. 2024 Oct 1;24(1):1085. doi: 10.1186/s12879-024-09937-2. BMC Infect Dis. 2024. PMID: 39354399 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous